News Agency
The Times

Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO

  • Written by PR Newswire

HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The principal investigators of the study are Prof. Bai...

Read more: Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of...

Executive Recruitment And The Value Of Executive Recruitment Agencies In Modern Hiring

Finding the right leadership talent is one of the most important decisions an organisation can make. Strong leaders influence company culture, business performance, strategic direction, and long-term growth. As competition for experienced executives continues to increase, executive recruitment has become a... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion